Arcellx, Inc.

Organisation

800 Bridge Parkway, Redwood City, CA, United States, 94065

Headquarters

Employees

Healthcare

Industry

Rami Elghandour

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-004 for the treatment of AML and MDS. Further, the company focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize nito-cel and next-generation autologous and non-autologous CAR-T cell therapy products. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Price

Target

Arcellx, Inc. (ACLX) Price vs Consensus Price Target

As per the chart shown above, analysts believe that the Arcellx, Inc. (ACLX) share price will touch around $111.07 in next 12-months.

Currently 21 wall-street analysts regularly analyze the financials of Arcellx, Inc. on a frequent basis to provide recommendations along with target share price. 21 analysts offering 12-month price forecasts for Arcellx, Inc. (ACLX) have a share price target of $111.07. This median of share price forecast represents a -3.23% downside from the latest price of $114.78 as on 01.04.26.

Arcellx, Inc. (ACLX) Share Price Forecast

Home

US Stocks

Arcellx, Inc. (ACLX)

Arcellx, Inc. Stock Forecast

Arcellx, Inc. Stock Forecast & Price Target (Analyst Recommendation) | INDmoney

Percentage Difference

Arcellx, Inc. (ACLX): Difference between Current Price & Median Forecasted Price

Below is a chart showing the percentage difference between Arcellx, Inc.'s share price and its median forecast price. As on 01.04.26, the difference is -37.45%

Arcellx, Inc. Forecast and Target Price

Arcellx, Inc. (ACLX) Share Price Forecast

Arcellx, Inc. (ACLX) Price vs Consensus Price Target

Arcellx, Inc. (ACLX) Share Price Forecast v/s Share Price Today

Arcellx, Inc. (ACLX): Difference between Current Price & Median Forecasted Price

Arcellx, Inc. (ACLX) Share Price Technical Analysis

50 Day Moving Average v/s Current Share Price

200 Day Moving Average v/s Current Share Price